97 related articles for article (PubMed ID: 3106247)
21. T cell early activation antigens expressed by peripheral lymphocytes in Crohn's disease.
Fais S; Pallone F; Squarcia O; Boirivant M; Pozzilli P
J Clin Lab Immunol; 1985 Feb; 16(2):75-6. PubMed ID: 2985788
[TBL] [Abstract][Full Text] [Related]
22. The monoclonal antibodies Trop-4 and 4F2 detect the same membrane antigen that is expressed at an early stage of lymphocyte activation and is retained on secondary lymphocytes.
Suomalainen HA
J Immunol; 1986 Jul; 137(2):422-7. PubMed ID: 3487571
[TBL] [Abstract][Full Text] [Related]
23. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma.
Habeshaw JA; Lister TA; Stansfeld AG; Greaves MF
Lancet; 1983 Mar; 1(8323):498-501. PubMed ID: 6131211
[TBL] [Abstract][Full Text] [Related]
24. Correlation of monoclonal antibody phenotyping and cellular DNA content in non-Hodgkin's lymphoma. The Southeastern Cancer Study Group experience.
Wain SL; Braylan RC; Borowitz MJ
Cancer; 1987 Nov; 60(10):2403-11. PubMed ID: 3499212
[TBL] [Abstract][Full Text] [Related]
25. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
26. Non-Hodgkin's lymphomas: immunologic prognostic studies.
Hadzi-Pecova L; Petrusevska G; Stojanovic A
Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
[TBL] [Abstract][Full Text] [Related]
27. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens.
Pallone F; Fais S; Squarcia O; Biancone L; Pozzilli P; Boirivant M
Gut; 1987 Jun; 28(6):745-53. PubMed ID: 3040543
[TBL] [Abstract][Full Text] [Related]
28. Expression and the functional role of a p70/75 interleukin 2-binding molecule in human B cell.
Saiki O; Tanaka T; Doi S; Kishimoto S
J Immunol; 1988 Feb; 140(3):853-8. PubMed ID: 2828472
[TBL] [Abstract][Full Text] [Related]
29. Low-grade lymphomas. Expression of developmentally regulated B-cell antigens.
Cossman J; Neckers LM; Hsu S; Longo D; Jaffe ES
Am J Pathol; 1984 Apr; 115(1):117-24. PubMed ID: 6201073
[TBL] [Abstract][Full Text] [Related]
30. Expression of Tac antigen by non-Hodgkin's lymphomas.
Weiss LM; Michie SA; Medeiros LJ; Strickler JG; Garcia CF; Warnke RA
Am J Clin Pathol; 1987 Oct; 88(4):483-5. PubMed ID: 2821794
[TBL] [Abstract][Full Text] [Related]
31. Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Studies in inflammatory bowel disease and after in vitro exposure to different stimuli.
Fais S; Pallone F
Gastroenterology; 1989 Dec; 97(6):1435-41. PubMed ID: 2531100
[TBL] [Abstract][Full Text] [Related]
32. Expression of interleukin 2 receptors on activated human B cells.
Waldmann TA; Goldman CK; Robb RJ; Depper JM; Leonard WJ; Sharrow SO; Bongiovanni KF; Korsmeyer SJ; Greene WC
J Exp Med; 1984 Nov; 160(5):1450-66. PubMed ID: 6092511
[TBL] [Abstract][Full Text] [Related]
33. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
[TBL] [Abstract][Full Text] [Related]
34. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
Sakarou M; Eisele L; Dührsen U; Hüttmann A
Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
[TBL] [Abstract][Full Text] [Related]
36. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Czuczman MS; Fallon A; Mohr A; Stewart C; Bernstein ZP; McCarthy P; Skipper M; Brown K; Miller K; Wentling D; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-López AJ; Bernstein SH
Semin Oncol; 2002 Feb; 29(1 Suppl 2):36-40. PubMed ID: 11842387
[TBL] [Abstract][Full Text] [Related]
37. Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin lymphomas and leukaemias: possible influence on growth pattern and leukaemic behaviour.
Stauder R; Greil R; Schulz TF; Thaler J; Gattringer C; Radaskiewicz T; Dierich MP; Huber H
Clin Exp Immunol; 1989 Aug; 77(2):234-8. PubMed ID: 2673591
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content.
Cotner T; Williams JM; Christenson L; Shapiro HM; Strom TB; Strominger J
J Exp Med; 1983 Feb; 157(2):461-72. PubMed ID: 6296263
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
[TBL] [Abstract][Full Text] [Related]
40. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
